Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peceleganan (PL-5) Spray in Mild Diabetic Foot Ulcer Infections
NCT06189638Phase 2Active, not recruiting
- Sponsor
- Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd.
- Start
- Jan 2024
- Primary completion
- Apr 2027
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of peceleganan in diabetic foot ulcer (DFU), sponsored by Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd.. Started Jan 2024; status: active, not recruiting.
02
Drugs
peceleganan
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on NCT06189638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06189638.